CNR2 and breast cancer: Nearly complete ablation of BC cells was achieved with CmbT120C/D265C-WB692-CB2 at a dose of 128 J/cm2, resulting in 2.1 ± 2.3% and 3.6 ± 1.5% viability for RT4 and RT112 cells, respectively.